Core Viewpoint - Diginex Limited is convening an Extraordinary General Meeting (EGM) to seek shareholder approval for significant changes to its share capital structure, including an increase in authorized share capital and a share consolidation to comply with Nasdaq listing requirements [1][2][3]. Group 1: Shareholder Meeting and Proposals - The EGM is scheduled for April 13, 2026, for shareholders of record as of March 27, 2026 [1]. - The company aims to increase its authorized share capital to US$200,000, divided into 3,960,000,000 ordinary shares and 40,000,000 preferred shares, by adding 3,000,000,000 ordinary shares [2]. - A share consolidation will occur where every eight existing ordinary shares will be consolidated into one new ordinary share, and the same applies to preferred shares [2]. Group 2: Impact of Authorized Share Capital Changes - The authorized share capital changes will not alter the proportionate ownership interest of shareholders and are not expected to materially affect the company's overall market capitalization [3]. - These changes are intended to ensure compliance with Nasdaq's continued listing requirements, particularly the minimum bid price requirement [3][8]. Group 3: Nasdaq Compliance and Future Actions - Diginex received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price was below $1.00 for 30 consecutive business days [7][8]. - The company has until September 21, 2026, to regain compliance, with the possibility of an additional 180-day grace period if necessary [9]. - If compliance is not achieved, the company's ordinary shares may face delisting from Nasdaq [9]. Group 4: Company Overview - Diginex Limited is a sustainable RegTech business that focuses on helping businesses and governments manage ESG, climate, and supply chain data through advanced technology [10].

Core Insights - Registrar Corp has acquired CMC Medical Devices, enhancing its capabilities in clinical, regulatory, and compliance services for medical device manufacturers [1][2] - The acquisition aims to integrate Registrar Corp's network with CMC's offerings, facilitating a combined service to assist companies in navigating regulatory frameworks [2][4] - This development is expected to ease global expansion for manufacturers by minimizing expenses, challenges, and timelines associated with regulatory compliance [4] Group 1: Acquisition Details - Registrar Corp acquired CMC Medical Devices, a company based in Spain, specializing in clinical and regulatory services [1] - CMC operates in over 70 countries, focusing on Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) compliance [1][3] Group 2: Service Integration - The acquisition allows Registrar Corp to provide services as an authorized representative in multiple regions, including Australia, China, the US, the UK, the EU, and Switzerland [2] - Registrar Corp will manage Free Sale Certificates, streamlining export documentation and supporting quicker product approvals [3] Group 3: Benefits to Manufacturers - The combined services will support medical device and IVD firms throughout all phases of product compliance and commercialization [5] - CMC's clinical network enables Registrar Corp to offer additional services such as data gathering plans and post-market clinical follow-up reporting [3][5]